Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0PQJDH
ADC Name
MEDI2228
Synonyms
MEDI2228
   Click to Show/Hide
Organization
AstraZeneca (Top20 MNC) (Originator)
Drug Status
Phase 1 (discontinued)
Drug-to-Antibody Ratio
2
Structure
Antibody Name
BCMA-Ab1
  Antibody Info 
Antigen Name
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)
  Antigen Info 
Payload Name
SG3199 (SC-DR002)
  Payload Info 
Therapeutic Target
Human deoxyribonucleic acid (hDNA)
  Target Info 
Linker Name
Mal-PEG8-Val-Ala-PABC
  Linker Info 
Conjugate Type
Reactive Cysteines
Combination Type
tesirine
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
Indication Phase 1 Phase 1/2 Phase 2 Phase 2/3 Phase 3 New Drug Application Approved
Multiple myeloma
1 Trials
Trial ID
NCT03489525
General Information of The ADMET Data Related to This ADC(2027 Update)
Absorption
Click To Hide/Show 24 Absorption Data Related to This Level
Standard Type Value Units Description Reference
Maximum Observed Concentration (Cmax) 231.3 ng/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.0125 mg/kg.
 [1]
Time to Maximum Concentration (Tmax) 0.07 day
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.0125 mg/kg.
 [1]
Area Under the Concentration-Time Curve (AUC) 1162 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.0125 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 1306 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.0125 mg/kg, AUCinf.
 [1]
Maximum Observed Concentration (Cmax) 478.7 ng/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.025 mg/kg.
 [1]
Time to Maximum Concentration (Tmax) 0.11 day
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.025 mg/kg.
 [1]
Area Under the Concentration-Time Curve (AUC) 1757 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.025 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 1896 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.025 mg/kg, AUCinf.
 [1]
Maximum Observed Concentration (Cmax) 872.8 ng/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.05 mg/kg.
 [1]
Time to Maximum Concentration (Tmax) 0.28 day
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.05 mg/kg.
 [1]
Area Under the Concentration-Time Curve (AUC) 4393 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.05 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 4404 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.05 mg/kg, AUCinf.
 [1]
Maximum Observed Concentration (Cmax) 1828 ng/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.10 mg/kg.
 [1]
Time to Maximum Concentration (Tmax) 0.15 day
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.10 mg/kg.
 [1]
Area Under the Concentration-Time Curve (AUC) 8635 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.10 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 9002 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.10 mg/kg, AUCinf.
 [1]
Maximum Observed Concentration (Cmax) 2702 ng/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.14 mg/kg.
 [1]
Time to Maximum Concentration (Tmax) 0.07 day
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.14 mg/kg.
 [1]
Area Under the Concentration-Time Curve (AUC) 14040 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.14 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 14060 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.14 mg/kg, AUCinf.
 [1]
Maximum Observed Concentration (Cmax) 3897 ng/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.20 mg/kg.
 [1]
Time to Maximum Concentration (Tmax) 0.07 day
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.20 mg/kg.
 [1]
Area Under the Concentration-Time Curve (AUC) 16260 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.20 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 16780 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.20 mg/kg, AUCinf.
 [1]
Distribution
Click To Hide/Show 12 Distribution Data Related to This Level
Standard Type Value Units Description Reference
Area Under the Concentration-Time Curve (AUC) 1162 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.0125 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 1306 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.0125 mg/kg, AUCinf.
 [1]
Area Under the Concentration-Time Curve (AUC) 1757 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.025 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 1896 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.025 mg/kg, AUCinf.
 [1]
Area Under the Concentration-Time Curve (AUC) 4393 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.05 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 4404 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.05 mg/kg, AUCinf.
 [1]
Area Under the Concentration-Time Curve (AUC) 8635 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.10 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 9002 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.10 mg/kg, AUCinf.
 [1]
Area Under the Concentration-Time Curve (AUC) 14040 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.14 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 14060 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.14 mg/kg, AUCinf.
 [1]
Area Under the Concentration-Time Curve (AUC) 16260 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.20 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 16780 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.20 mg/kg, AUCinf.
 [1]
Metabolism
Click To Hide/Show 12 Metabolism Data Related to This Level
Standard Type Value Units Description Reference
Area Under the Concentration-Time Curve (AUC) 1162 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.0125 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 1306 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.0125 mg/kg, AUCinf.
 [1]
Area Under the Concentration-Time Curve (AUC) 1757 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.025 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 1896 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.025 mg/kg, AUCinf.
 [1]
Area Under the Concentration-Time Curve (AUC) 4393 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.05 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 4404 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.05 mg/kg, AUCinf.
 [1]
Area Under the Concentration-Time Curve (AUC) 8635 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.10 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 9002 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.10 mg/kg, AUCinf.
 [1]
Area Under the Concentration-Time Curve (AUC) 14040 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.14 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 14060 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.14 mg/kg, AUCinf.
 [1]
Area Under the Concentration-Time Curve (AUC) 16260 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.20 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 16780 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.20 mg/kg, AUCinf.
 [1]
Excretion
Click To Hide/Show 18 Excretion Data Related to This Level
Standard Type Value Units Description Reference
Area Under the Concentration-Time Curve (AUC) 1162 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.0125 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 1306 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.0125 mg/kg, AUCinf.
 [1]
Elimination Half-Life (t1/2) 7.476 day
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.0125 mg/kg.
 [1]
Area Under the Concentration-Time Curve (AUC) 1757 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.025 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 1896 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.025 mg/kg, AUCinf.
 [1]
Elimination Half-Life (t1/2) 4.755 day
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.025 mg/kg.
 [1]
Area Under the Concentration-Time Curve (AUC) 4393 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.05 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 4404 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.05 mg/kg, AUCinf.
 [1]
Elimination Half-Life (t1/2) 8.716 day
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.05 mg/kg.
 [1]
Area Under the Concentration-Time Curve (AUC) 8635 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.10 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 9002 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.10 mg/kg, AUCinf.
 [1]
Elimination Half-Life (t1/2) 6.988 day
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.10 mg/kg.
 [1]
Area Under the Concentration-Time Curve (AUC) 14040 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.14 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 14060 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.14 mg/kg, AUCinf.
 [1]
Elimination Half-Life (t1/2) 8.963 day
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.14 mg/kg.
 [1]
Area Under the Concentration-Time Curve (AUC) 16260 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.20 mg/kg, AUClast.
 [1]
Area Under the Concentration-Time Curve (AUC) 16780 ng*day/mL
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.20 mg/kg, AUCinf.
 [1]
Elimination Half-Life (t1/2) 6.677 day
Pharmacokinetic parameters of the MEDI2228 ADC following the first dose of cycle 1 in dose-escalation phase (Q3W), 0.20 mg/kg.
 [1]
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT03489525
PHASE1
A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma
Objective Response Rate (ORR)  NCT03489525
Phase 1
A phase 1, open-label study to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of MEDI2228 in subjects with relapsed/refractory multiple myeloma.
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 82.05
%
MM1.S cells
Plasma cell myeloma
Tumor Growth Inhibition value (TGI) 
≈ 90.46
%
MM1.S cells
Plasma cell myeloma
Tumor Growth Inhibition value (TGI) 
≈ 99.94
%
MM1.S cells
Plasma cell myeloma
Obtained from the Model Organism Data
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type Value Units Animal Model (No. of PDX)
Tumor Growth Inhibition value (TGI) 
≈ 67.99
%
CB17 SCID mice model
Tumor Growth Inhibition value (TGI) 
≈ 90.12
%
CB17 SCID mice model
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Effective Dose (EC50) 
189.7
ng/mL
RPMI-8226 cells
Plasma cell myeloma
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [2]
Patients Enrolled
Eligible patients must be &ge;18 years with relapsed/refractory multiple myeloma (IMWG criteria) who exhausted standard therapies, have measurable disease, ECOG 0-1, and adequate organ function. Exclusions include recent stem cell transplants (<90 days), CNS involvement, plasma cell disorders, or conditions interfering with safety assessments.
Administration Dosage
Single agent MEDI2228, ADC (antibody drug conjugate) will be administered to adult subjects with relapsed/refractory (R/R) multiple myeloma (MM).
Related Clinical Trial
NCT Number NCT03489525  Clinical Status PHASE1
Clinical Description A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma
Primary Endpoint
The study evaluates safety through monitoring adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs) from informed consent through 90 days post-treatment, including laboratory tests, vital signs, and ECG changes assessed up to 21 days after treatment completion.
Other Endpoint
Pharmacokinetic analysis measures MEDI2228 concentration, clearance, and half-life over 60 days post-treatment while assessing immunogenicity via anti-drug antibodies. Efficacy endpoints including objective response rate, clinical benefit rate, duration of response, progression-free survival, and overall survival are evaluated for up to three years post-enrollment.

   Click to Show/Hide
Experiment 2 Reporting the Activity Date of This ADC [3]
Efficacy Data Objective Response Rate (ORR)
61%
Patients Enrolled
Eligible pts were 18 years old with confirmed relapsed/refractory multiple myeloma (R/R MM) as defined by International Myeloma Working Group consensus criteria, had measurable disease, and had an Eastern Cooperative Oncology Group performance status 1. Pts had to have progressed after treatment with three classes of standard-of-care anti-myeloma drugs, including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and monoclonal antibodies (mAbs).

   Click to Show/Hide
Administration Dosage
Administered in the dose of 0.0125-0.20 mg/kg intravenously every 3 weeks (Q3W); The maximum tolerated dose was 0.14 mg/kg Q3W.
Related Clinical Trial
NCT Number NCT03489525  Clinical Status Phase 1
Clinical Description A phase 1, open-label study to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of MEDI2228 in subjects with relapsed/refractory multiple myeloma.
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [4]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 82.05%
Method Description
The inhibitory activity of MEDI-2228 against cancer cell growth was evaluated in various human cancer cell lines in vivo. The cells were treated with 0.3 mg/kg MEDI-2228.
In Vivo Model NSG mice model
In Vitro Model Plasma cell myeloma MM1.S cells CVCL_8792
Experiment 2 Reporting the Activity Date of This ADC [4]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 90.46%
Method Description
The inhibitory activity of MEDI-2228+NK against cancer cell growth was evaluated in various human cancer cell lines in vivo. The cells were treated with 0.3 mg/kg MEDI-2228.
In Vivo Model NSG mice model
In Vitro Model Plasma cell myeloma MM1.S cells CVCL_8792
Experiment 3 Reporting the Activity Date of This ADC [4]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 99.94%
Method Description
The inhibitory activity of MEDI-2228+NK+Dara against cancer cell growth was evaluated in various human cancer cell lines in vivo. The cells were treated with 0.3 mg/kg MEDI-2228.
In Vivo Model NSG mice model
In Vitro Model Plasma cell myeloma MM1.S cells CVCL_8792
Obtained from the Model Organism Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [5]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 67.99%
Method Description
The inhibitory activity of MEDI-2228 against cancer cell growth was evaluated in various human cancer cell lines in vivo.The cells were treated with 0.4 mg/kg MEDI-2228.
In Vivo Model CB17 SCID mice model
Experiment 2 Reporting the Activity Date of This ADC [5]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 90.12%
Method Description
The inhibitory activity combination of M2 and btz for 2 weeks against cancer cell growth was evaluated in various human cancer cell lines in vivo.
In Vivo Model CB17 SCID mice model
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [5]
Efficacy Data Half Maximal Effective Dose (EC50)
189.7 ng/mL
Method Description
The inhibitory activity of MEDI-2228 against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model Plasma cell myeloma RPMI-8226 cells CVCL_0014
References
Ref 1 Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma
Ref 2 MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma
Ref 3 Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Multiple Myeloma. Blood (2020) 136 (Supplement 1): 2627.
Ref 4 BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression. Clin Cancer Res. 2021 Oct 1;27(19):5376-5388.
Ref 5 A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma. Leukemia. 2020 Aug;34(8):2150-2162.